Risperidone-associated Steatohepatitis and Excessive Weight-gain

Abstract

We report on a 17-year-old girl who developed steatohepatitis and marked weight gain during risperidone treatment for paranoid psychosis. Viral, metabolic, and other causes of liver disease were excluded. Although the exact mechanism of antipsychotic associated weight gain is unclear, the impact of risperidone on the serotonergic system and on neuropeptide Y, a stimulator of food intake, might be implicated in the development of obesity. Additionally, weight gain-related hyperleptinemia could be a link between overweight and hepatotoxicity via cytokines. Physicians should routinely monitor body weight, liver function, fasting blood glucose, and lipid profiles in children and adolescents at the beginning of risperidone therapy. Additionally, patients complaining about weight gain should be monitored more carefully during the maintenance phase.

References

• 1 Allison D B, Casey D E. Antipsychotic-induced weight gain: a review of the literature.  J Clin Psychiatry. 2001;  62 Suppl 7 22-31
• 2 Angelucci F, Aloe L, Gruber S H, Fiore M, Mathe A A. Chronic antipsychotic treatment selectively alters nerve growth factor and neuropeptide Y immunoreactivity and the distribution of choline acetyl transferase in rat brain regions.  Int J Neuropsychopharmacol. 2000;  3(1) 3-25
• 3 Baptista T, Lacruz A, Angeles F, Silvera R, de Mendoza S, Mendoza M T, Hernandez L. Endocrine and metabolic abnormalities involved in obesity associated with typical antipsychotic drug administration.  Pharmacopsychiatry. 2001;  34(6) 23-31
• 4 Faggioni R, Jones-Carson J, Reed D A, Dinarello C A, Feingold K R, Grunfeld C, Fantuzzi G. Leptin-deficient (ob/ob) mice are protected from T cell-mediated hepatotoxicity: role of tumor necrosis factor alpha and IL-18.  Proc Natl Acad Sci U S A. 2000;  9(5) 367-72
• 5 Kumra S, Herion D, Jacobsen L K, Briguglia C, Grothe D. Case study: risperidone-induced hepatotoxicity in pediatric patients.  J Am Acad Child Adolesc Psychiatry. 1997;  36(5) 01-5
• 6 McIntyre R S, McCann S M, Kennedy S H. Antipsychotic metabolic effects: weight gain, diabetes mellitus, and lipid abnormalities.  Can J Psychiatry. 2001;  46(3) 73-81
• 7 Szigethy E, Wiznitzer M, Branicky L A, Maxwell K, Findling R L. Risperidone-induced hepatotoxicity in children and adolescents? A chart review study.  J Child Adolesc Psychopharmacol. 1999;  9 (2) 3-8
• 8 Virkkunen M, Wahlbeck K, Rissanen A, Naukkarinen H, Franssila-Kallunki A. Decrease of energy expenditure causes weight increase in olanzapine treatment - a case study.  Pharmacopsychiatry. 2002;  35 (3) 24-6
• 9 Wetterling T. Bodyweight gain with atypical antipsychotics. A comparative review.  Drug Saf. 2001;  24(1) 9-73
• 10 Wieczorek I, Schulz C, Jarry H, Lehnert H. The effects of the selective serotonin reuptake-inhibitor fluvoxamine on body weight in Zucker rats are mediated ba corticotropin-releasing hormone.  Int J Obes Relat Metab Disord. 2001;  25(10) 566-9